Alzheimer's disease (AD), the most common cause of dementia in the elderly, is now the fourth major cause of death in the developed world after heart disease, cancer, and stroke (Yankner et al., 1991; Lendon et al., 1997) . A definitive diagnosis requires postmortem examination of brain tissue for the presence of distinctive AD histopathology, including filamentous inclusions in neuronal cell bodies (neurofibrillary tangles) and processes (neurites) as well as extracellular deposits of amyloid-␤ peptide (A␤) in senile plaques and within the walls of leptomeningeal/cerebral vessels in the neocortex, olfactory bulb, and hippocampus (Glenner et al., 1984; Selkoe et al., 1987) .
Genetic investigations have demonstrated that AD is a heterogeneous disorder with several known etiologies (St George-Hyslop, 2000) , including: dosage imbalance for chromosome 21 as occurs in Down syndrome (DS) and mutations in the amyloid precursor protein (APP) gene on chromosome 21, the presenilin-1 (PS-1) gene on chromosome 14, and the presenilin-2 (PS-2) gene on chromosome 1 in autosomal dominant early-onset FAD. Current evidence suggests that all the early-onset FAD mutations result in elevated production of A␤ (particularly the fibrillogenic 42 amino acid form, A␤1-42) from APP (Selkoe, 2000) .
Transgenic approaches can directly test whether the overexpression of wt or mutant APP, PS-1, or PS-2 genes leads to AD-type abnormalities and thus provide insight into the molecular mechanism(s) of disease. Over the past several years, numerous groups have generated mice with various features of AD using APP gene fragments and cDNAs. Although these transgenic studies have provided conclusive evidence that transgenic mice can develop A␤ deposits, at present it remains unclear how these different models relate to each other as each model makes different assumptions with regard to the APP cDNA (695, 751, or 770 amino acid) and the heterologous promoter utilized to drive the temporal and spatial expression of the transgene.
Our efforts have been directed toward establishing an accurate genetic model for AD by introducing entire genomic copies of either wild-type or mutant human APP (Lamb et al., 1993 (Lamb et al., , 1995 (Lamb et al., , 1997 
